Global Peptide Therapeutics Pipeline Insight 2015
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Peptides are small molecules of varying molecular masses that consist of amino acids joined with the help of peptide bonds (CONH2). One end of the molecule consists of carboxyl (COOH2) group while the other end has amino (NH2) group giving rise to polarity. Biologically, they are very important and found to play an important role in various anabolic and catabolic processes. They are essential component of cell signaling pathways, immune system, hormonal systems, enzymatic systems and others important systems in the body. Owing to same building blocks, sometimes they are confused with the proteins which are more or less biochemically similar in nature. Technically, peptide consists of upto 50 amino acids in the chain while proteins are much longer chains of amino acids.
Researchers have identified several peptides which are necessary part of body systems that could be used for pharmacological purposes during disease incidence. Peptides could be easily designed and modified according to necessity due to which they have high safety and efficacy profile. They are small in size due to which they can easily enter inside the cell and interact with desired molecules. They have low immunotoxicity due to which they have high tolerability and could be administered to patient of all age group. Various routes of delivery could be observed in this category; they could be injected or orally administrated to patients and newer methods like inhalation is presently under investigation. High bioavailability makes them highly potent as they are highly absorbable due to which lesser amount of therapeutics is required.
Use of peptides in several disease indications has been already proved by investigators and several of them are already available in market. Rapid introduction in market has become possible due to development of high yielding SPPS and LPPS methods. Both have same function of peptide synthesis but they differ in biochemistry due to which their commercial utilization severely depends upon quantity, molecular weight, length of peptide and cost arbitrage. Purification costs also vary from process to process due which it becomes imperative to have effective method that can save time and money. Industrial biotechnologists are working with different modalities to develop new methods having fewer investments per unit peptide therapeutics produced per batch.
Peptide based therapeutics have highly diverse market with numerous categories that could be further divided into several sub categories. They have high market penetration rates across the globe and generate significant amount of revenues. Burgeoning pressure on pharmaceutical companies to come forth with highly effective therapeutic products along with higher cost arbitrage is driving the peptide based therapeutics market. Strong clinical pipeline allows the pharmaceutical companies to regularly introduce their products in global market. Both extreme ends could be observed in this segment reflecting divergence and interest of pharmaceutical companies. Some categories like insulin are quite mature while peptide cancer vaccine market segment is still emerging and has to pass through various phases of industry life cycle.
Peptide Segment Covered In Report:
Cyclic-Peptide, Polypeptide, Glycopeptide, Glycopeptide, Oligopeptide, Depsipeptide, Neuropeptide, Dipeptides, Natriuretic Peptide, Lipopeptide, Opioid Peptide, Peptide Vaccine, Antimicrobial Cationic Peptide & Insulin
“Global Peptide Therapeutics Pipeline Insight 2015” Report Highlights:
Peptides are small molecules of varying molecular masses that consist of amino acids joined with the help of peptide bonds (CONH2). One end of the molecule consists of carboxyl (COOH2) group while the other end has amino (NH2) group giving rise to polarity. Biologically, they are very important and found to play an important role in various anabolic and catabolic processes. They are essential component of cell signaling pathways, immune system, hormonal systems, enzymatic systems and others important systems in the body. Owing to same building blocks, sometimes they are confused with the proteins which are more or less biochemically similar in nature. Technically, peptide consists of upto 50 amino acids in the chain while proteins are much longer chains of amino acids.
Researchers have identified several peptides which are necessary part of body systems that could be used for pharmacological purposes during disease incidence. Peptides could be easily designed and modified according to necessity due to which they have high safety and efficacy profile. They are small in size due to which they can easily enter inside the cell and interact with desired molecules. They have low immunotoxicity due to which they have high tolerability and could be administered to patient of all age group. Various routes of delivery could be observed in this category; they could be injected or orally administrated to patients and newer methods like inhalation is presently under investigation. High bioavailability makes them highly potent as they are highly absorbable due to which lesser amount of therapeutics is required.
Use of peptides in several disease indications has been already proved by investigators and several of them are already available in market. Rapid introduction in market has become possible due to development of high yielding SPPS and LPPS methods. Both have same function of peptide synthesis but they differ in biochemistry due to which their commercial utilization severely depends upon quantity, molecular weight, length of peptide and cost arbitrage. Purification costs also vary from process to process due which it becomes imperative to have effective method that can save time and money. Industrial biotechnologists are working with different modalities to develop new methods having fewer investments per unit peptide therapeutics produced per batch.
Peptide based therapeutics have highly diverse market with numerous categories that could be further divided into several sub categories. They have high market penetration rates across the globe and generate significant amount of revenues. Burgeoning pressure on pharmaceutical companies to come forth with highly effective therapeutic products along with higher cost arbitrage is driving the peptide based therapeutics market. Strong clinical pipeline allows the pharmaceutical companies to regularly introduce their products in global market. Both extreme ends could be observed in this segment reflecting divergence and interest of pharmaceutical companies. Some categories like insulin are quite mature while peptide cancer vaccine market segment is still emerging and has to pass through various phases of industry life cycle.
Peptide Segment Covered In Report:
Cyclic-Peptide, Polypeptide, Glycopeptide, Glycopeptide, Oligopeptide, Depsipeptide, Neuropeptide, Dipeptides, Natriuretic Peptide, Lipopeptide, Opioid Peptide, Peptide Vaccine, Antimicrobial Cationic Peptide & Insulin
“Global Peptide Therapeutics Pipeline Insight 2015” Report Highlights:
- Global Peptide Therapeutics Market Overview
- Global Peptide Therapeutics Pipeline By Peptide Type
- Global Peptide Therapeutics Pipeline By Company, Indication & Phase
- Peptide Therapeutics Clinical Pipeline: 743 Peptides
- Majority Peptide Therapeutics in Preclinical Phase: 293 Peptides
- Commercially available Peptides: 126 Peptides
1. INTRODUCTION TO PEPTIDES
2. MECHANISM OF PEPTIDE THERAPEUTICS
3. GLOBAL PEPTIDE THERAPEUTICS MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Peptide Pipeline Overview
4. GLOBAL PEPTIDE THERAPEUTICS MARKET DYNAMICS
4.1 Market Growth Drivers
4.2 Commercialization Challenges
5. GLOBAL PEPTIDE THERAPEUTICS MARKET FUTURE PROSPECTS
6. INSULIN PIPELINE BY COMPANY, INDICATION & PHASE
6.1 Phase Research to till Registered
6.2 Marketed
7. PEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
7.1 Phase Research to till Registered
7.2 Marketed
8. CYCLIC PEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Phase Research to till Preregistration
8.2 Marketed
9. POLYPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Phase Research to till Phase-III
9.2 Marketed
10. GLYCOPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
10.1 Phase Research to till Registered
10.2 Marketed
11. LIPOPEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
11.1 Phase Research to till Phase-III
11.2 Phase: Marketed
12. OLIGOPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
12.1 Phase Research to till Preregistration
12.2 Marketed
13. DEPSI PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Phase Research to till Phase-III
13.2 Marketed
14. NEUROPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
14.1 Phase Preclinical to till Phase-II/III
14.2 Marketed
15. DIPEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
15.1 Phase Preclinical to till Phase-III
15.2 Marketed
16. NATRIURETIC PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
16.1 Phase Preclinical to till Phase-III
17. OPIOID PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
17.1 Phase Preclinical to till Preregistration
17.2 Marketed
18. PEPTIDE VACCINE PIPELINE BY COMPANY, INDICATION & PHASE
18.1 Phase Preclinical to till Phase-III
19. ANTIMICROBIAL CATIONIC PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
19.1 Phase Preclinical to till Phase-III
20. MULTIPLE PEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
20.1 Phase Preclinical to till Registered
20.2 Marketed
21. COMPETITIVE LANDSCAPE
21.1 Amgen
21.2 Amylin Pharmaceuticals
21.3 Corden Pharma (Peptisyntha)
21.4 GlaxoSmithKline
21.5 Ipsen
21.6 Lonza
21.7 Merck
21.8 PeptiDream
21.9 Roche
21.10 Sanofi
2. MECHANISM OF PEPTIDE THERAPEUTICS
3. GLOBAL PEPTIDE THERAPEUTICS MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Peptide Pipeline Overview
4. GLOBAL PEPTIDE THERAPEUTICS MARKET DYNAMICS
4.1 Market Growth Drivers
4.2 Commercialization Challenges
5. GLOBAL PEPTIDE THERAPEUTICS MARKET FUTURE PROSPECTS
6. INSULIN PIPELINE BY COMPANY, INDICATION & PHASE
6.1 Phase Research to till Registered
6.2 Marketed
7. PEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
7.1 Phase Research to till Registered
7.2 Marketed
8. CYCLIC PEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Phase Research to till Preregistration
8.2 Marketed
9. POLYPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Phase Research to till Phase-III
9.2 Marketed
10. GLYCOPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
10.1 Phase Research to till Registered
10.2 Marketed
11. LIPOPEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
11.1 Phase Research to till Phase-III
11.2 Phase: Marketed
12. OLIGOPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
12.1 Phase Research to till Preregistration
12.2 Marketed
13. DEPSI PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Phase Research to till Phase-III
13.2 Marketed
14. NEUROPEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
14.1 Phase Preclinical to till Phase-II/III
14.2 Marketed
15. DIPEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
15.1 Phase Preclinical to till Phase-III
15.2 Marketed
16. NATRIURETIC PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
16.1 Phase Preclinical to till Phase-III
17. OPIOID PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
17.1 Phase Preclinical to till Preregistration
17.2 Marketed
18. PEPTIDE VACCINE PIPELINE BY COMPANY, INDICATION & PHASE
18.1 Phase Preclinical to till Phase-III
19. ANTIMICROBIAL CATIONIC PEPTIDE PIPELINE BY COMPANY, INDICATION & PHASE
19.1 Phase Preclinical to till Phase-III
20. MULTIPLE PEPTIDES PIPELINE BY COMPANY, INDICATION & PHASE
20.1 Phase Preclinical to till Registered
20.2 Marketed
21. COMPETITIVE LANDSCAPE
21.1 Amgen
21.2 Amylin Pharmaceuticals
21.3 Corden Pharma (Peptisyntha)
21.4 GlaxoSmithKline
21.5 Ipsen
21.6 Lonza
21.7 Merck
21.8 PeptiDream
21.9 Roche
21.10 Sanofi
LIST OF FIGURES
Figure 1-1: Components of Peptide
Figure 1-2: Features of Peptide Therapeutics
Figure 2-1: Benefits of Peptide Modifications
Figure 2-2: Benefits of Computational Methods
Figure 2-3: Different Types of Peptide Formulation Vehicles
Figure 2-4: Mechanism of Vibativ
Figure 2-5: Mechanism of Liraglutide
Figure 2-6: Mechanism of Goserelin
Figure 2-7: Formulation of Orally Administrated Peptide Therapeutics
Figure 3-1: Global Peptide Market (US$ Billion), 2013-2018
Figure 3-2: Insulin Pipeline by Phase (%), 2015
Figure 3-3: Insulin Pipeline by Phase (Number), 2015
Figure 3-4: Peptides Pipeline by Phase (%), 2015
Figure 3-5: Peptides Pipeline by Phase (Number), 2015
Figure 3-6: Cyclic Peptide Pipeline by Phase (%), 2015
Figure 3-7: Cyclic Peptide Pipeline by Phase (Number), 2015
Figure 3-8: Polypeptide Pipeline by Phase (%), 2015
Figure 3-9: Polypeptide Pipeline by Phase (Number), 2015
Figure 3-10: Glycopeptide Pipeline by Phase (%), 2015
Figure 3-11: Glycopeptide Pipeline by Phase (Number), 2015
Figure 3-12: Lipopeptide Pipeline by Phase (%), 2015
Figure 3-13: Lipopeptide Pipeline by Phase (Number),2014
Figure 3-14: Oligopeptide Pipeline by Phase (%), 2015
Figure 3-15: Oligopeptide Pipeline by Phase (Number), 2015
Figure 3-16: Depsi Peptide Pipeline by Phase (%), 2015
Figure 3-17: Depsi Peptide Pipeline by Phase (Number), 2015
Figure 3-18: Neuropeptide Pipeline by Phase (%), 2015
Figure 3-19: Neuropeptide Pipeline by Phase (Number), 2015
Figure 3-20: Dipeptide Pipeline by Phase (%), 2015
Figure 3-21: Dipeptide Pipeline by Phase (Number), 2015
Figure 3-22: Natriuretic Peptide Pipeline by Phase (%), 2015
Figure 3-23: Natriuretic Peptide Pipeline by Phase (Number), 2015
Figure 3-24: Opioid Peptide Pipeline by Phase (%), 2015
Figure 3-25: Opioid Peptide Pipeline by Phase (Number), 2015
Figure 3-26: Peptide Vaccine Pipeline by Phase (%), 2015
Figure 3-27: Peptide Vaccine Pipeline by Phase (Number), 2015
Figure 3-28: Antimicrobial-Cationic-Peptide Pipeline by Phase (%), 2015
Figure 3-29: Antimicrobial-Cationic-Peptide Pipeline by Phase (Number), 2015
Figure 3-30: Multiple Peptide Pipeline by Phase (%), 2015
Figure 3-31: Multiple Peptide Pipeline by Phase (Number), 2015
Figure 4-1: Global Peptide Therapeutics Market Growth Drivers
Figure 4-2: Global Peptide Therapeutics Market Commercialization Challenges
Figure 1-1: Components of Peptide
Figure 1-2: Features of Peptide Therapeutics
Figure 2-1: Benefits of Peptide Modifications
Figure 2-2: Benefits of Computational Methods
Figure 2-3: Different Types of Peptide Formulation Vehicles
Figure 2-4: Mechanism of Vibativ
Figure 2-5: Mechanism of Liraglutide
Figure 2-6: Mechanism of Goserelin
Figure 2-7: Formulation of Orally Administrated Peptide Therapeutics
Figure 3-1: Global Peptide Market (US$ Billion), 2013-2018
Figure 3-2: Insulin Pipeline by Phase (%), 2015
Figure 3-3: Insulin Pipeline by Phase (Number), 2015
Figure 3-4: Peptides Pipeline by Phase (%), 2015
Figure 3-5: Peptides Pipeline by Phase (Number), 2015
Figure 3-6: Cyclic Peptide Pipeline by Phase (%), 2015
Figure 3-7: Cyclic Peptide Pipeline by Phase (Number), 2015
Figure 3-8: Polypeptide Pipeline by Phase (%), 2015
Figure 3-9: Polypeptide Pipeline by Phase (Number), 2015
Figure 3-10: Glycopeptide Pipeline by Phase (%), 2015
Figure 3-11: Glycopeptide Pipeline by Phase (Number), 2015
Figure 3-12: Lipopeptide Pipeline by Phase (%), 2015
Figure 3-13: Lipopeptide Pipeline by Phase (Number),2014
Figure 3-14: Oligopeptide Pipeline by Phase (%), 2015
Figure 3-15: Oligopeptide Pipeline by Phase (Number), 2015
Figure 3-16: Depsi Peptide Pipeline by Phase (%), 2015
Figure 3-17: Depsi Peptide Pipeline by Phase (Number), 2015
Figure 3-18: Neuropeptide Pipeline by Phase (%), 2015
Figure 3-19: Neuropeptide Pipeline by Phase (Number), 2015
Figure 3-20: Dipeptide Pipeline by Phase (%), 2015
Figure 3-21: Dipeptide Pipeline by Phase (Number), 2015
Figure 3-22: Natriuretic Peptide Pipeline by Phase (%), 2015
Figure 3-23: Natriuretic Peptide Pipeline by Phase (Number), 2015
Figure 3-24: Opioid Peptide Pipeline by Phase (%), 2015
Figure 3-25: Opioid Peptide Pipeline by Phase (Number), 2015
Figure 3-26: Peptide Vaccine Pipeline by Phase (%), 2015
Figure 3-27: Peptide Vaccine Pipeline by Phase (Number), 2015
Figure 3-28: Antimicrobial-Cationic-Peptide Pipeline by Phase (%), 2015
Figure 3-29: Antimicrobial-Cationic-Peptide Pipeline by Phase (Number), 2015
Figure 3-30: Multiple Peptide Pipeline by Phase (%), 2015
Figure 3-31: Multiple Peptide Pipeline by Phase (Number), 2015
Figure 4-1: Global Peptide Therapeutics Market Growth Drivers
Figure 4-2: Global Peptide Therapeutics Market Commercialization Challenges
